Piramal Pharma Solutions announces the launch of Xcelerate Integrated Solutions

Piramal Pharma Solutions has launched its Xcelerate Integrated Solutions platform to address a rapidly growing market need. This platform will serve the increasing demand from pharmaceutical firms, both large and small, for preferred partnerships with organizations that can provide world-class solutions across a range of verticals – drug discovery, drug substance, drug product, and clinical trial services. Xcelerate Integrated Solutions stands out for its flexibility and versatility. The platform provides integrated solutions for orphan diseases, niche therapies, and fast track medicines, where the volume requirements are small, while also having the capacity and track record to address large volume needs of metabolic diseases and neuroscience therapies.

The distinct footprint of PPS, with around half its sites in the East and the other half in the West, allows customers to manufacture the final API or drug product out of the West, while back integrating into starting materials and intermediates out of its sites in the East. The Xcelerate platform sets the foundation through which customers can accelerate their programs from the clinic through approval and launch. With a track record of successfully executing over 70 integrated programs in the recent past, and the associated learnings, the company has now invested in capabilities and systems to provide a seamless experience to their customers.